BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22890925)

  • 1. Managing apheresis complications during the hematopoietic stem cell collection.
    Marlow SD; House M
    Methods Mol Biol; 2012; 904():93-6. PubMed ID: 22890925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic progenitor cell collection.
    Marlow SD; House M
    Methods Mol Biol; 2012; 904():85-91. PubMed ID: 22890924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of apheresis in children.
    Michon B; Moghrabi A; Winikoff R; Barrette S; Bernstein ML; Champagne J; David M; Duval M; Hume HA; Robitaille N; Bélisle A; Champagne MA
    Transfusion; 2007 Oct; 47(10):1837-42. PubMed ID: 17880609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring blood for CD34+ cells to determine timing of Hematopoietic Progenitor Cells Apheresis.
    Vaughn ML; Waller EK
    Methods Mol Biol; 2012; 904():79-83. PubMed ID: 22890923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic Progenitor Cell Apheresis processing.
    Hamilton ES; Waller EK
    Methods Mol Biol; 2012; 904():97-109. PubMed ID: 22890926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected citrate toxicity and severe hypocalcemia during apheresis.
    Uhl L; Maillet S; King S; Kruskall MS
    Transfusion; 1997 Oct; 37(10):1063-5. PubMed ID: 9354826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and kinetics of bone marrow processing and enrichment of haematopoietic progenitor cells (HPC) by a large-volume apheresis procedure.
    Cassens U; Ostkamp-Ostermann P; Garritsen H; Kelsch R; Ostermann H; Kienast J; Kiehl M; Buechner T; van de Loo J; Juergens H; Sibrowski W
    Bone Marrow Transplant; 1997 Apr; 19(8):835-40. PubMed ID: 9134178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic plasma exchange performed in tandem with hemodialysis without supplemental calcium in the apheresis circuit.
    Zhao Y; Ibrahim H; Bailey JA; Linden J; Hickson E; Haynes S; Greene M; Vauthrin M; Weinstein R
    J Clin Apher; 2017 Jun; 32(3):154-157. PubMed ID: 27172986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What's happening: an overview of potential adverse reactions associated with apheresis technology.
    Maurício R; de Sousa G; Seghatchian J
    Transfus Apher Sci; 2005 Nov; 33(3):351-6. PubMed ID: 16226918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications of donor apheresis.
    Winters JL
    J Clin Apher; 2006 Jul; 21(2):132-41. PubMed ID: 15880355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of citrate reactions in patients with multiple myeloma during peripheral blood stem cell leukapheresis.
    Adamski J; Griffin AC; Eisenmann C; Milone MC; Sachais BS
    J Clin Apher; 2010; 25(4):188-94. PubMed ID: 20818713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors.
    Yuan S; Ziman A; Smeltzer B; Lu Q; Goldfinger D
    Transfusion; 2010 Feb; 50(2):478-86. PubMed ID: 19843285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for adverse events during collection of peripheral blood stem cells.
    Donmez A; Arik B; Tombuloglu M; Cagirgan S
    Transfus Apher Sci; 2011 Aug; 45(1):13-6. PubMed ID: 21727028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres.
    Crocco I; Franchini M; Garozzo G; Gandini AR; Gandini G; Bonomo P; Aprili G
    Blood Transfus; 2009 Jan; 7(1):35-8. PubMed ID: 19290078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells.
    Lane TA; Bashey A; Carrier E; Holman P; Castro J; Mullen M; Ward DM; Ada O; Ball ED
    Cytotherapy; 2004; 6(4):318-27. PubMed ID: 16146884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of immediate adverse effects associated with therapeutic apheresis.
    McLeod BC; Sniecinski I; Ciavarella D; Owen H; Price TH; Randels MJ; Smith JW
    Transfusion; 1999 Mar; 39(3):282-8. PubMed ID: 10204591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis.
    Lefrère F; Zohar S; Beaudier S; Audat F; Ribeil JA; Ghez D; Varet B; Cavazzana-Calvo M; Dal Cortivo L; Letestu R; McIntyre E; Brouzes C
    Transfusion; 2007 Oct; 47(10):1851-7. PubMed ID: 17880611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation techniques in apheresis: from heparin to citrate and beyond.
    Lee G; Arepally GM
    J Clin Apher; 2012; 27(3):117-25. PubMed ID: 22532037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apheresis techniques for collection of peripheral blood progenitor cells.
    Moog R
    Transfus Apher Sci; 2004 Dec; 31(3):207-20. PubMed ID: 15556469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.